Cargando…
Gene expression profile and response to trastuzumab–docetaxel-based treatment in breast carcinoma
BACKGROUND: Resistance to trastuzumab is often observed in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer and has been shown to involve multiple potential mechanisms. We examined the ability of microarray analyses to determine the potential markers of pathological...
Autores principales: | Végran, F, Boidot, R, Coudert, B, Fumoleau, P, Arnould, L, Garnier, J, Causeret, S, Fraise, J, Dembélé, D, Lizard-Nacol, S |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768465/ https://www.ncbi.nlm.nih.gov/pubmed/19755993 http://dx.doi.org/10.1038/sj.bjc.6605310 |
Ejemplares similares
-
Transcriptional expression of 8 genes predicts pathological response to first-line docetaxel + trastuzumab-based neoadjuvant chemotherapy
por: Schmitt, Esther, et al.
Publicado: (2015) -
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
por: Arnould, L, et al.
Publicado: (2006) -
Only Missense Mutations Affecting the DNA Binding Domain of P53 Influence Outcomes in Patients with Breast Carcinoma
por: Végran, Frédérique, et al.
Publicado: (2013) -
A Short Caspase-3 Isoform Inhibits Chemotherapy-Induced Apoptosis by Blocking Apoptosome Assembly
por: Végran, Frédérique, et al.
Publicado: (2011) -
T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival
por: Ladoire, S, et al.
Publicado: (2011)